Survey Study on Patient Reported Outcomes for Small Cell Lung Cancer

Overview

Información sobre este estudio

The purpose of this study of adults who have been diagnosed with SCLC aims to gain a better understanding of participants’ experiences with SCLC symptoms and impacts, and to refine a patient-reported outcome (PRO) measure, the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ©), for use in future trials of SCLC treatments.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Is at least 18 years of age.
  • Has a clinician-confirmed diagnosis of limited or extensive stage SCLC.
  • Has an ECOG Performance Status of 0 to 3 at the time of screening.
  • Can read, write, and speak English well enough to understand and complete the informed consent form (ICF), take part in the interview process, and complete all study procedures.

Exclusion Criteria:

  • Has a clinically significant1 current or past history of a personality disorder, bipolar disorder, schizophrenia or other psychotic disorder, obsessive compulsive disorder, cognitive disorder, post-traumatic stress disorder, or intellectual disability.
  • Has a recent (12-month) history of clinically significant1 drug or alcohol abuse or dependence, excluding nicotine.
  • Has been hospitalized for COVID-19 within the previous 12 weeks or, at the time of study screening, is experiencing unresolved COVID-19 symptoms from a current or prior case of COVID-19 as any medical condition or disorder (e.g., symptomatic brain metastases; significant cognitive, auditory, or visual impairment) that, in the opiniHn of the site investigator or study director, could compromise participant’s ability to give written informed consent and/or prevent or interfere with his or her ability to comply with study procedures and provide meaningful information about his or her SCLC experience.

Eligibility last updated 2/24/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Terence Sio, M.D., M.S.

Cerrado; inscripción por invitación

¿Qué es esto? (?)
"Close"
El estudio no está abierto para todos los que cumplen con los criterios de elegibilidad, sino solamente para las personas que el equipo del estudio ha invitado a participar.

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20533481

Mayo Clinic Footer